Simple research view

VRTX · Vertex Pharmaceuticals Incorporated

$514.56 -1.26% Sep 10 close

Detected setup Trend Only · Setup Score 71/100

Stand aside — setup invalidated

Setup score 71, but distribution days reach 5 or more — stand aside until the condition resets.

1 independent risk warning also present. Review before relying on the bullish setup.

Ask about VRTX

Switch to Advanced for indicator panels, raw grades, provenance, drawing tools, and full technical tables.

$VRTX

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is a large-cap Pharmaceuticals: Major company in the Health Technology sector with a market cap of $130B.

Health Technology Pharmaceuticals: Major stock Stage 2 · Advancing Base 2

$514.56 latest close

⚠ Risk Signals

Rising Wedge prior_advance=33.4%, converging=yes, narrowing=2%, touches=upper:3/lower:3, trigger=broke

Bearish structure on the daily chart — a heads-up for anyone holding, not a short signal. Does not affect the bullish setup score.

Join to Watchlist $VRTX Share card

Verdict · setup score 71/100 · data Sep 10 close · 1 session old

Stand aside — setup invalidated

Setup score 71, but distribution days reach 5 or more — stand aside until the condition resets.

Review six verdicts Inspect chart

Earnings

Normal technical setup

No sourced report date Event risk is not modelled for this symbol

Deterministic evidence

VRTX-1.26%

Sector proxy · XLV-0.55%

Broad market · SPY-0.60%

Same completed session window ending 2026-09-10. VRTX was -0.71 points vs XLV. -0.66 points vs SPY.

Session internals Weak

Rule: closed flat-to-down and in the bottom third of the range. Judged on internals, not on the size of the move.

Vs prior close-1.26% From the open-0.82% Range position3% GapNo gap

QQQ confirmationConfirming (-1.06%) SMH confirmationConfirming (-2.44%)

Price bars, sourced event fields, and benchmark math only. This can adjust displayed short-term conviction; it does not change the stored scanner score or readiness.

Ask a Legend to interpret this evidence → Commentary only — never scanner evidence or a sizing recommendation.

Price $514.56 -1.3% Sep 10 close

52W High $560.25 8.2% below high

Wks Since High 0w

Base Depth 7.8% 8.2% today

RS Rank 39 percentile of scan

SMA 50 $510.30

Avg Vol 1,290,771

Rel Vol (Sep 10) 0.63×

More stats

52W Low $374.17

Tight Wks 0

Base B2

SMA 200 $467.58

RS Line vs High -7.9%

RS Line Slope +2.3% ▲

Group Rank #27/58

ADR% 2.2%

ATR(14) $11.43 (2.2%)

Vol Pace (live) N/A

U/D Vol 0.90

A/D Days 21A / 9D

A/D Rating A+

VDU Bars 0/10 d

Position in 52-week range 75thpercentile of the 52-week range

$374.17low

$560.25high

VRTX Chart

Interactive price, volume, RS, RSI, and MACD charts are available after sign in.

Create a free account to load the full interactive chart for VRTX.

Create Free Account

Technical Analysis Report Card

$VRTX · $514.56 · as of 2026-09-10 · multi-factor read

/ 100

Technicals 62/100

Reference read from price & volume only — the verdict at the top of the page decides the action.

Trend · Daily / Weekly / Monthly

Daily ▬ Sideways / consolidating

Weekly ▲ Uptrend

Monthly ▲ Uptrend

Moving Averages

50-day$510.30 ↑

100-day$477.11 ↑

200-day$467.58 ↑

Bullish (50 > 200)

RSI (14)

Reading43.5 · Bearish

Bearish momentum — sellers in control.

MACD (12/26/9)

StateWeakening

Histogram-5.333

Weakening — MACD slipped below its signal line. Histogram contracting.

Bollinger Bands (20,2)

%B / Width13% · 11.8%

Near the lower band — under pressure or oversold.

Volume · Buyer vs Seller

Up/Down vol0.9 · Neutral

Rel volume0.63×

Balanced — up/down volume is roughly even; no clear hand. Recent volume is easing versus its baseline.

Support & Resistance

R · $533.67swing level

R · $546.17swing level

R · $555.69swing level

Price · $514.56now

S · $467.43swing level

S · $450.67swing level

S · $431.01swing level

Fibonacci · Uptrend swing

23.6%$525.33

38.2%$503.72

50.0%$486.26

61.8%$468.80

78.6%$443.94

Retracement support zones measured from the recent swing low up to the high.

The verdict is free. The trade plan is Pro.

Unlock the exact entry, stop-loss, profit target, and reward-to-risk for VRTX — plus the full 500+ symbol scanner and Ask-the-Legends chat.

Start your 7-day free trial →

Weekly uptrendMonthly uptrendAbove 200-day MA50/200 bullish

Want this read in a legend's voice? Ask a Legend about VRTX

Generic technical analysis generated mechanically from price & volume — educational research only, not financial advice or a personalized recommendation. Levels are illustrative; confirm on your own chart. New to these terms? →

Legend Verdicts 6 methodology checks

Who would consider this setup, why it qualifies, and what blocks it — calculated from the same deterministic methodology rules used across Legend AI.

Council consensus: 5 of 6 legends are Watching — building, not yet a confirmed buy.

Minervini

Watch

Minervini C

Trend-template read: 6/10 pass; wait for the soft misses to improve.

Passing evidence

1.1 Price > 150-day MA AND 200-day MAPrice $514.56, MA150 $471.88, MA200 $467.58

1.2 150-day MA > 200-day MAMA150 $471.88 vs MA200 $467.58

Failing evidence

1.8 RS rank ≥ 70 (prefer ≥ 85)RS rank 48

2. Quarterly EPS growth ≥ 25%From SEPA scan

6/10 checks

Method → Playbook → Ask →

O'Neil

Avoid

O'Neil D

CANSLIM read: fails C: Quarterly EPS acceleration ≥ 25%.

Passing evidence

N: Near 52-week high or RS line new high8.2% below high | RS line new high: False

S: Base tightness (ATR% ≤ 4.5%)ATR% 2.22%

Failing evidence

L: RS rank ≥ 80 (IBD leadership)RS rank 48

C: Quarterly EPS acceleration ≥ 25%Data unavailable

2/8 checks

Method → Playbook → Ask →

Weinstein

Watch

Weinstein C

Stage-analysis read: Stage 2 is present; 2 supporting checks need improvement.

Passing evidence

Stage 2 (Advancing phase) confirmedStage 2 (Advancing)

Price above 30-week MA (200-day proxy)Price $514.56 vs MA200 $467.58

Failing evidence

Volume expansion above averageVolume ratio 0.63x

Relative strength ≥ 60RS 48

5/7 checks

Method → Playbook → Ask →

Livermore

Watch

Livermore B

Pivotal-point read: constructive evidence is present, but relative strength is unresolved.

Passing evidence

Price$514.56

Distance from 52-week high8.2% below high

Failing evidence

Relative strengthRS 48

Volume vs average0.63x

3/6 checks

Method → Playbook → Ask →

Darvas

Watch

Darvas B

Box-theory read: constructive evidence is present, but relative strength is unresolved.

Passing evidence

Price$514.56

Distance from 52-week high8.2% below high

Failing evidence

Relative strengthRS 48

Volume vs average0.63x

3/6 checks

Method → Playbook → Ask →

Wyckoff

Watch

Wyckoff B

Supply-and-demand read: constructive evidence is present, but relative strength is unresolved.

Passing evidence

Price$514.56

Distance from 52-week high8.2% below high

Failing evidence

Relative strengthRS 48

Volume vs average0.63x

3/6 checks

Method → Playbook → Ask →

Base & Breakout

Breakout follow-through

No active breakout tracked — Legend AI monitors daily for pivot-point breaks. What's a breakout?

Unlock Base & Breakout Tracking

RS Line vs SPY 52-week relative strength · blue = RS line · dashed = MA50 · dot = NH ▲ Rising

Accumulation / Distribution last 65 sessions · green = acc on high vol · red = dist on high vol Net +8 A+

Minervini · Grade Card

Fundamentals & leadership quality — Minervini’s published criteria · 2/7 met

C 2/7 criteria

Separate score from the Minervini Trend Template (7/8): the Trend Template grades the price structure, this grades the company & leadership (earnings, sales, margins, RS rank). A stock can ride a clean trend while its fundamentals lag, so the two often differ by design — they are not the same checklist.

✗ EPS acceleration ≥25% QoQ —

✗ Revenue growth ≥20% YoY +9%

✗ Gross margin ≥30% —

✗ ROE ≥17% —

✗ RS rating ≥80 (leadership) 48

✓ Stage 2 uptrend (Weinstein) Stage 2

✓ Within 25% of 52W high -8.2%

Method Playbook

Trade it like Darvas EXACT LEVELS · PRO

Minervini O'Neil Livermore Weinstein Darvas Wyckoff

Darvas B · Watch — The deterministic methodology check is Watch; wait for the failing or incomplete criteria to improve before the trigger can qualify.

Pivot

Pro level

Published-method rule: Use the top of the active Darvas box near the high as the mechanical breakout boundary.
Evidence: Canonical setup geometry is available with Pro.

Entry trigger

Pro level

Published-method rule: Require price to clear the box top with volume confirmation; movement inside the box remains observation, not a trigger.
Evidence: Canonical setup geometry is available with Pro.

Initial stop

Pro level

Published-method rule: Start below the active box support or the canonical structural stop that proves the breakout failed.
Evidence: Canonical setup geometry is available with Pro.

Trail

Rule-based

Published-method rule: As higher boxes form, raise the stop beneath the newest confirmed box floor; the stop moves up only.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.

Exit / invalidation

Pro level

Published-method rule: Exit when price breaks the active box floor or decisively falls back through the breakout structure.
Evidence: Canonical setup geometry is available with Pro.

Deterministic educational plan, not a recommendation. No order or stop is changed automatically. Method and sources →

The published-method workflow is public. Unlock exact pivot, entry, stop, target, and sizing with Pro →

Pattern Analysis

Trend Only

71 setup score

RS Score 48

Trend template 7/8

Why This Setup?

Trend Only · schematic

Gatekeeper 7/8 | Strong trend (7/8) | Stage 2

The Universal Edge Check · context only

What the setup still has going for it, recorded for later. The verdict above stands — these principles do not overrule it.

1/7 universals met

A relative-strength leader — not met RS rank 39 — laggard
Risk is defined — not met No stop — undefined risk
Asymmetric reward — partly met No target set
Clear of earnings — partly met Report date unknown
Not chasing (in range) — partly met Pivot distance unknown
Volume confirms — partly met 0.6× average — light
In a confirmed uptrend — met Stage 2 · Trend template 7/8

Why these seven? → The Universal Edge

Minervini Trend Template

7/8

Grades the price structure — moving-average stacking, distance from the 52-week high/low, and relative strength above the ≥70 uptrend bar. This is the technical trend check; the company's fundamentals and ≥80 RS leadership are scored separately in the Grade Card.

Price above SMA 150 & 200 $514.56 vs SMA150 $471.88 / SMA200 $467.58

SMA 150 above SMA 200 SMA150 $471.88 vs SMA200 $467.58

SMA 200 trending up Slope +11.37 over 20 days

SMA 50 above SMA 150 & 200 SMA50 $510.30

Price above SMA 50 $514.56 vs SMA50 $510.30

30%+ above 52-week low +37.5% from $374.17

Within 25% of 52-week high -8.2% from $560.25

RS score above 70 RS 48

Fundamentals

52W Range

75%

Mkt Cap SEC

130.4B

Rev YoY

+9%

EPS TTM

$15.32

P/E TTM

33.6x

Float

253M

Company

Company profile

Vertex Pharmaceuticals Incorporated

VRTX · NASDAQ · Health Technology · Pharmaceuticals: Major

Weekly Context

Multi-timeframe signals from weekly bars

W. Trend

8/8

W. RS

W. Support

$412.27

W. Resist

$560.25

Weekly Structure

Trend Neutral

Tight Weeks 0

Confirmation Neutral

Scan History

20× streak

Sep 11

Trend Only ✓ Gate

Sep 11

Trend Only ✓ Gate

Sep 11

Trend Only ✓ Gate

Sep 11

Trend Only ✓ Gate

Sep 11

Trend Only ✓ Gate

Sep 10

Trend Only ✓ Gate

71 0.0%

Get the full picture on VRTX

Pro members see entry/stop/target levels, R:R ratios, intraday alerts, and every setup detected across 500+ symbols daily.

Start 7-Day Free Trial